Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice

Future Oncology
Cliff MolifeAna B Oton

Abstract

To describe treatment patterns and outcomes for advanced/metastatic non-small-cell lung cancer (aNSCLC) treated with single-agent or combination ramucirumab (ramucirumab-based) and/or immune checkpoint inhibitor (ICI-based) therapy. Retrospective study of aNSCLC patients (n = 4054) identified in the Flatiron Health database, who received at least two treatment lines including ramucirumab- and/or ICI-based regimens between December 2014 and May 2017. Median overall survival (95% CI) from aNSCLC diagnosis was 29.3 (25.5-33.0) months for patients receiving sequential ramucirumab- and ICI-based therapy (n = 245), 15.1 (12.6-18.2) months for patients receiving sequences including ramucirumab- without ICI-based therapy (n = 112), and 23.1 (21.9-24.2) months for patients receiving ICI-based therapy without ramucirumab-based therapy in sequence (n = 3697). Results provide real-world survival estimates for aNSCLC treated with sequences including ramucirumab- and/or ICI-based therapies.

References

Apr 8, 2009·Proceedings of the American Thoracic Society·Thomas E Stinchcombe, Mark A Socinski
May 12, 2009·The American Journal of Cardiology·José G Díez, Marc Cohen
Sep 28, 2010·Lancet·Frank Pasqualone
Dec 24, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Keith L DavisJames A Kaye
Mar 10, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Denis Moro-SibilotPhilipp A Schnabel
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christian ManegoldEverett Vokes
Dec 19, 2016·Journal of the American College of Surgeons·Richard L Schilsky
Aug 15, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaGregory Masters
Oct 24, 2017·Journal of the National Cancer Institute·Sean KhozinRichard Pazdur
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators

❮ Previous
Next ❯

Citations

May 12, 2019·International Journal of Molecular Sciences·Marilina García-Aranda, Maximino Redondo
Jul 17, 2020·Therapeutic Advances in Medical Oncology·Robert J Walsh, Ross A Soo
Apr 4, 2021·International Journal of Molecular Sciences·Florus C de JongDan Theodorescu
Jul 25, 2021·International Journal of Environmental Research and Public Health·Andrea SpiniGiuseppe Roberto
Nov 24, 2021·Current Opinion in Oncology·Chiara LazzariVanesa Gregorc

❮ Previous
Next ❯

Software Mentioned

SAS
REVEL

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.